Display options
Cite
She S, Bian S, Huo R, et al. Degradable Organically-Derivatized Polyoxometalate with Enhanced Activity against Glioblastoma Cell Line. Sci Rep. 2016;6:33529doi: 10.1038/srep33529.
She, S., Bian, S., Huo, R., Chen, K., Huang, Z., Zhang, J., Hao, J., & Wei, Y. (2016). Degradable Organically-Derivatized Polyoxometalate with Enhanced Activity against Glioblastoma Cell Line. Scientific reports, 633529. https://doi.org/10.1038/srep33529
She, Shan, et al. "Degradable Organically-Derivatized Polyoxometalate with Enhanced Activity against Glioblastoma Cell Line." Scientific reports vol. 6 (2016): 33529. doi: https://doi.org/10.1038/srep33529
She S, Bian S, Huo R, Chen K, Huang Z, Zhang J, Hao J, Wei Y. Degradable Organically-Derivatized Polyoxometalate with Enhanced Activity against Glioblastoma Cell Line. Sci Rep. 2016 Sep 23;6:33529. doi: 10.1038/srep33529. PMID: 27658479; PMCID: PMC5034237.
Copy Download .nbib Format: NLM
Share it on

Sci Rep. 2016 Sep 23;6:33529. doi: 10.1038/srep33529.

Degradable Organically-Derivatized Polyoxometalate with Enhanced Activity against Glioblastoma Cell Line.

Scientific reports

Shan She, Shengtai Bian, Ruichao Huo, Kun Chen, Zehuan Huang, Jiangwei Zhang, Jian Hao, Yongge Wei

Affiliations

  1. Department of Chemistry, Tsinghua University, Beijing 100084, China.
  2. State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China.
  3. Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing 100084, China.
  4. Laboratory Animal Center, Fourth Military Medical University, Xi'an 710032, China.

PMID: 27658479 PMCID: PMC5034237 DOI: 10.1038/srep33529

Abstract

High efficacy and low toxicity are critical for cancer treatment. Polyoxometalates (POMs) have been reported as potential candidates for cancer therapy. On accounts of the slow clearance of POMs, leading to long-term toxicity, the clinical application of POMs in cancer treatment is restricted. To address this problem, a degradable organoimido derivative of hexamolybdate is developed by modifying it with a cleavable organic group, leading to its degradation. Of note, this derivative exhibits favourable pharmacodynamics towards human malignant glioma cell (U251), the ability to penetrate across blood brain barrier and low toxicity towards rat pheochromocytoma cell (PC12). This line of research develops an effective POM-based agent for glioblastoma inhibition and will pave a new way to construct degradable anticancer agents for clinical cancer therapy.

References

  1. J Am Chem Soc. 2008 Jul 16;130(28):8874-5 - PubMed
  2. J Am Chem Soc. 2010 Jan 13;132(1):14-5 - PubMed
  3. Small. 2013 Oct 25;9(20):3455-61 - PubMed
  4. Expert Rev Neurother. 2008 Oct;8(10):1497-506 - PubMed
  5. Nat Commun. 2014 Mar 04;5:3422 - PubMed
  6. Angew Chem Int Ed Engl. 2016 Feb 12;55(7):2592-5 - PubMed
  7. Chem Rev. 2010 Oct 13;110(10):6009-48 - PubMed
  8. Angew Chem Int Ed Engl. 2008;47(14):2626-30 - PubMed
  9. J Am Chem Soc. 2015 May 13;137(18):5916-22 - PubMed
  10. Chemistry. 2015 Jul 13;21(29):10537-47 - PubMed
  11. Nat Rev Neurol. 2009 Aug;5(8):419-26 - PubMed
  12. J Am Chem Soc. 2001 Feb 7;123(5):886-97 - PubMed
  13. Angew Chem Int Ed Engl. 2011 Apr 26;50(18):4184-8 - PubMed
  14. Nat Clin Pract Oncol. 2008 Aug;5(8):476-86 - PubMed
  15. J Am Chem Soc. 2015 Mar 11;137(9):3197-200 - PubMed
  16. Chemistry. 2012 Jul 9;18(28):8681-91 - PubMed
  17. Chem Soc Rev. 2012 Nov 21;41(22):7384-402 - PubMed
  18. J Am Chem Soc. 2013 Nov 13;135(45):17155-60 - PubMed
  19. J Am Chem Soc. 2006 Apr 19;128(15):4938-9 - PubMed
  20. Chem Rev. 1998 Feb 5;98(1):327-358 - PubMed
  21. J Am Chem Soc. 2010 May 5;132(17):5956-7 - PubMed
  22. Chem Rev. 1998 Feb 5;98(1):239-272 - PubMed
  23. Chem Rev. 2015 Jun 10;115(11):4893-962 - PubMed
  24. Nature. 2014 Nov 27;515(7528):545-9 - PubMed
  25. Nat Rev Clin Oncol. 2013 Jan;10(1):14-26 - PubMed
  26. Angew Chem Int Ed Engl. 2014 Oct 13;53(42):11182-5 - PubMed
  27. Cancer Res. 1987 Nov 15;47(22):5846-52 - PubMed
  28. Angew Chem Int Ed Engl. 2011 May 9;50(20):4708-11 - PubMed
  29. Chem Rev. 2004 Feb;104(2):1175-200 - PubMed
  30. Angew Chem Int Ed Engl. 2016 Feb 5;55(6):2122-6 - PubMed
  31. Biomaterials. 2013 Jul;34(22):5628-39 - PubMed
  32. Chemistry. 2014 Dec 15;20(51):16987-94 - PubMed
  33. Chem Soc Rev. 2012 Nov 21;41(22):7605-22 - PubMed
  34. J Am Chem Soc. 2015 Jun 24;137(24):7881-8 - PubMed
  35. Chem Rev. 2015 Oct 14;115(19):11079-108 - PubMed
  36. Chem Commun (Camb). 2015 Jun 25;51(50):10119-22 - PubMed
  37. Chem Rev. 2015 Aug 12;115(15):7001-45 - PubMed
  38. Proc Nutr Soc. 1974 Dec;33(3):299-305 - PubMed
  39. J Am Chem Soc. 2001 May 2;123(17):4083-4 - PubMed
  40. Science. 2014 Sep 12;345(6202):1326-30 - PubMed
  41. J Am Chem Soc. 2005 Dec 14;127(49):17158-9 - PubMed
  42. J Am Chem Soc. 2012 Sep 12;134(36):14982-90 - PubMed

Publication Types